Dear Label_Name,

Greetings! I hope you are well.

I am writing on behalf of an international publishing house, Science and Education Publishing, USA (http://www.sciepub.com).

Science and Education Publishing (SciEP) is a multidisciplinary open access publisher of Journals covering the fields of Science, Technology and Medicine. All SciEP publications are subject to high-quality peer review, editorial and production processes and are freely available online.

Welcome to the April, 2013 edition of SciEP newsletter, providing monthly summaries of articles on science & education related topics of interest to scientist and professionals. The mission of our journals is to provide an open access forum for publishing new findings on issues pertinent to scientific and academic field. We also invite you to submit original research papers, review articles, short reports, or case studies are considered for publication in our Multidisciplinary Journals.

American Journal of Public Health Research
DOI: 10.12691/ajphr-1-1-3

The Implementation of a Tele-Homecare System with Service Oriented Architecture and HL7 Message Transmission Standard
Ching-Sung Wang

American Journal of Medical and Biological Research
DOI: 10.12691/ajmbr-1-1-2

The Influence of Ethanol on Pyruvate Kinases Activity in Vivo, in Vitro, in Silico
Lelevich Sergey Vladimirovich, Khrustalev Vladislav Victorovich, Barkovsky Eugene Victorovich, Shedogubova Tatyana Aleksandrovna

American Journal of Medical Sciences and Medicine
DOI: 10.12691/ajmsm-1-1-1

Clinical and Histological Features in Wegener Granulomatosis
Li Cavoli Gioacchino, Passantino Rita, Bono Luisa, Tortorici Calogera, Ferrantelli Angelo, Giammarresi Carlo, Rotolo Ugo

American Journal of Infectious Diseases and Microbiology
DOI: 10.12691/ajidm-1-1-2

The Curse of Lymphatic Filariasis: Would the Continual Use of Diethylcarbamazine Eliminate this Scourge in Papua New Guinea?
Anne Lanham, Lillian Mwanri

We have released issues of some journals on February 2013.
American Journal of Public Health Research
American Journal of Medical Sciences and Medicine
American Journal of Medical and Biological Research
American Journal of Pharmacological Sciences
American Journal of Clinical Medicine Research
American Journal of Nursing Research
American Journal of Cancer Prevention
American Journal of Medicine Studies
American Journal of Infectious Diseases and Microbiology
American Journal of Cardiovascular Disease Research
American Journal of Biomedical Research
American Journal of Mechanical Engineering
American Journal of Microbiological Research
Journal of Preventive Medicine
American Journal of Food and Nutrition
American Journal of Hypertension Research
American Journal of Sports Science and Medicine
Journal of Cancer Research and Treatment
American Journal of Zoological Research
Journal of Biomedical Engineering and Technology
American Journal of Microbiological Research
Biomedical Science and Engineering

We are pleased to announce that submissions are now being accepted for peer review for all the journals across all our subject areas in SciEP.

Please submit your manuscript via our online submission system:
http://www.sciepub.com/author/signin

To unsubscribe from our mailing list, please click on the following link: unsubscribe

I am looking forward to hearing from you.

Kind regards,

David Rain
Email:join@sciepub.com
Science and Education Publishing (http://www.sciepub.com)

The COVID-19 Vaccination Debate: Should Patients with Celiac Disease be Vaccinated with COVID-19 Vaccine?

Gabriel Samasca

Department of Immunology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania

Abstract: More and more patients with celiac disease are asking us “Should I be vaccinated against COVID-19, or not? What to do?” These are unknown things, we live in new times. What we can do is gather information and present it to you in the following. My colleagues, Professor Hugh James Freeman and Professor Aaron Lerner will give you answers in 2 articles of high academic level “COVID-19 AND CELIAC DISEASE” and “COV-2 IN CELIAC DISEASE: A PATHOGEN OR JUST ALONG FOR THE RIDE?”, which I invite you to read. We have also a nice article “IS THERE IS A LINK BETWEEN COVID-19 AND CELIAC DISEASE?” from USA. As Editor-in-chief, I will present you official information from official websites.

Keywords: celiac disease, patients, COVID-19 vaccine

Received January 01, 2021; Revised January 16, 2021; Accepted January 21, 2021

Citation: Gabriel Samasca, The COVID-19 Vaccination Debate: Should Patients with Celiac Disease be Vaccinated with COVID-19 Vaccine?. International Journal of Celiac Disease, 9 (1). 1-2. January 2021. doi:10.12691/ijcd-9-1-6

1. Introduction

Vaccination is the only way in a pandemic. But the effectiveness of the COVID-19 vaccine in patients with celiac disease is not yet known.

2. Material and Methods

We aimed to gather official information from various official websites to find out the answer to the question: Should patients with celiac disease be vaccinated with anti-SAR COV2 vaccine?

3. Results

We have learned the contraindications of COVID-19 vaccination on a few official sites. The most relevant information is from the Centre for Disease Control and Prevention (CDC) and World Health Organization (WHO).

We found answers to the Centre for Disease Control and Prevention website on his web page Updated on Jan. 1, 2021, related Information about the Pfizer-BioNTech COVID-19 Vaccine:, on Section “Who should not get vaccinated”. Here we find the following words:

“If you have had a severe allergic reaction (anaphylaxis) or an immediate allergic reaction—even if it was not severe—to any ingredient in an mRNA COVID-19 vaccine, you should not get an mRNA COVID-19 vaccine.*

If you have had a severe allergic reaction (anaphylaxis) or an immediate allergic reaction—even if it was not severe—after getting the first dose of the vaccine, you should not get another dose of an mRNA COVID-19 vaccine.*

An immediate allergic reaction means a reaction within 4 hours of getting vaccinated, including symptoms such as hives, swelling, or wheezing (respiratory distress).

This includes allergic reactions to polyethylene glycol (PEG) and polysorbate. Polysorbate is not an ingredient in either mRNA COVID-19 vaccine but is closely related to PEG, which is in the vaccines. People who are allergic to PEG or polysorbate should not get an mRNA COVID-19 vaccine.” [1]

We found other answers to the World Health Organization website on his web page Updated on Jan. 12 2021, on section “Who can take the Pfizer-BioNTech COVID-19 vaccine?” Here we find the following words:

“People with allergies

People with a history of severe allergic reaction to any component of the vaccine should not take it.

Pregnant and breastfeeding women

Pregnant women are at higher risk of severe COVID-19 than non-pregnant women, and COVID-19 has been associated with an increased risk of pre-term birth. However due to insufficient data, WHO does not recommend the vaccination of pregnant women at this time. In case a pregnant woman has an unavoidable risk high of exposure (e.g. a health worker), vaccination may be considered in discussion with their healthcare provider. If a breastfeeding woman is part of a group (e.g. health workers) recommended for vaccination, vaccination can be offered. WHO does not recommend discontinuing breastfeeding after vaccination.

Children

The vaccine has only been tested in children above 16 years of age. Therefore, at this time, WHO does not recommend vaccination of children below 16 years of age, even if they belong to a high-risk group.

People with known medical conditions

The vaccine has been found to be safe and effective in people with various conditions that are associated with increased risk of severe disease. This includes hypertension, diabetes, asthma, pulmonary, liver or kidney disease, as well as chronic infections that are stable and controlled. Further studies are required for the impacts on immune-compromised persons. The interim recommendation is that immune-compromised persons who are part of a group recommended for vaccination may be vaccinated, though when possible, not before receiving information and counselling. Persons living with HIV are at higher risk of severe COVID-19 disease. Limited safety data exists on HIV-infected persons with well controlled disease from the clinical trials. Known HIV-positive vaccine recipients should be informed, and when possible, counselled in relation to the available data.

People who have or had COVID-19 already

Vaccination can be offered to people who have had COVID-19 in the past. But given the limited vaccine supply, individuals may wish to defer their own COVID-19 vaccination for up to 6 months from the time of SARS-CoV-2 infection. As more data becomes available on duration of immunity after infection, this time period may be adjusted. Testing for prior infection is not recommended for the purpose of vaccine decision-making.

Travellers

At present, WHO does not support the introduction of requirements for proof of vaccination against COVID-19 for international travelers as a condition for exiting or entering a country or for travelling internationally. See WHO’s interim guidance on international travel during the pandemic.” [2]

4. Conclusions

A multidisciplinary team consisting of the family doctor, the specialist doctor and the infectious disease doctor should give their consent for each patient with celiac disease, child or adult, whether or not they fall into one of the above risk categories.

References

[1]   | https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/Pfizer-BioNTech.html.
[2]   | https://www.who.int/news-room/feature-stories/detail/who-can-take-the-pfizer-biontech-covid-19--vaccine.